7. Boston Scientific Corporation (NYSE:BSX)
Stock Upside: 60.39%
Market Capitalization: $69.52 billion
Number of Hedge Fund Holders: 106
Boston Scientific Corporation (NYSE:BSX) is one of the most promising healthcare stocks according to Wall Street analysts. On June 4, Truist Securities lowered its price target on Boston Scientific Corporation (NYSE:BSX) from $85 to $64, while keeping its Buy rating on the stock. Richard Newitter, the analyst on record, cited a growing slowdown in demand for the company’s Watchman heart device.
The Watchman is a small implant inserted into the heart to prevent blood clots from forming and traveling to the brain. In other words, the device is designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AFib). It serves as a one-time alternative to lifelong blood thinners.
According to Newitter, the trouble began building when Boston Scientific’s Q4 2025 results showed that Watchman sales came in about 1% below analyst expectations. Then when Boston Scientific CEO Michael Mahoney spoke at Bernstein’s annual conference on May 27, he disclosed that doctors were increasingly opting to combine Watchman procedures with other cardiac treatments in a single appointment rather than scheduling them as standalone procedures. To Newitter, this shift in clinical practice is directly cutting into Watchman’s procedure volumes. Even Mahoney himself told investors to expect Watchman revenue to remain essentially flat from Q1 through Q2 and likely into Q3 2026 because of the shift.
Boston Scientific Corporation (NYSE:BSX) is a medical device company. It develops, manufactures, and markets a broad portfolio of technologies for interventional medical specialties, and its products include drug-eluting stents, structural heart therapies like the Watchman left atrial appendage closure device, and electrophysiology mapping and ablation systems.
